Clinical trials: Cellulitis
TNF-receptor Associated Periodic Syndromes (TRAPS)
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
- Trial name
- NCT01242813
- Testing
- ACZ885
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Infections, Gram-positive Bacterial
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to…
- Trial name
- FAST2 (NCT00077675)
- Testing
- Telavancin, vancomycin or antistaphylococcal penicillin
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Cumberland Pharmaceuticals
Infections
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
The purpose of this study is to provide data documenting the efficacy of daptomycin in elderly patients aged ≥ 65 years with complicated Skin and Soft Tissue Infections.
- Trial name
- NCT01184872
- Testing
- Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs)
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-2 (NCT03377803)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 15 sites in United States
- Volunteers
- 262 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Skin Infection
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA.
- Trial name
- CG400549 (NCT01593761)
- Testing
- CG400549
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CrystalGenomics, Inc.
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients-1
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-1 (NCT03377790)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 18 sites in United States
- Volunteers
- 266 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Bacterial Infections
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.
- Trial name
- cSSSI (NCT00424190)
- Testing
- IV Vancomycin plus IV Aztreonam, Ceftaroline
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 698 people
- Sponsor
- Forest Laboratories
Wound Infection, Abscess
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a…
- Conditions
- Wound Infection, Abscess, Systemic Inflammation, Cellulitis
- Trial name
- SOLO II (NCT01252732)
- Testing
- Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
- Where
- United States
- Volunteers
- 1,019 people
- Sponsor
- Melinta Therapeutics, Inc.
Skin Diseases, Infectious
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
- Trial name
- CSSI (NCT00865280)
- Testing
- PTK 0796, linezolid, moxifloxacin
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Paratek Pharmaceuticals Inc
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS1 (NCT00091819)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 862 people
- Sponsor
- Cumberland Pharmaceuticals
Skin and Subcutaneous Tissue Bacterial Infections
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This study was designed to evaluate the efficacy of delafloxacin patients with acute bacterial skin and soft tissue infections (ABSSSI).
- Trial name
- NCT01811732
- Testing
- Delafloxacin, Vancomycin, Aztreonam
- Where
- 50 sites in United States, Croatia and 5 more
- Volunteers
- 660 people
- Sponsor
- Melinta Therapeutics, Inc.
Abscess, Wound Infection
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT02127970
- Testing
- Dalbavancin
- Where
- 78 sites in United States, Bulgaria and 10 more
- Volunteers
- 698 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Skin Infections, Bacterial
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions…
- Trial name
- NCT00684177
- Testing
- Retapamulin Ointment, 1%
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 508 people
- Sponsor
- GlaxoSmithKline
Acute Bacterial Skin and Skin Structure Infection
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This was a Phase 4, multicenter, open-label safety study of a single 1200 milligrams (mg) IV infusion of oritavancin in adult participants on chronic warfarin with acute bacterial skin and skin structure infection (ABSSSI)…
- Trial name
- NCT02452918
- Testing
- Oritavancin, Warfarin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- The Medicines Company
Infections, Gram-Positive Bacterial, Abscess
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria.
- Conditions
- Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis
- Trial name
- FAST (NCT00061633)
- Testing
- Telavancin, Vancomycin or antistaphylococcal penicillin
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Cumberland Pharmaceuticals
Major Cutaneous Abscess, Cellulitis
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
- Conditions
- Major Cutaneous Abscess, Cellulitis, Erysipelas
- Trial name
- NCT01519778
- Testing
- TR701 FA
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin Infection
The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown
Postoperative medicinal grade honey in post-operative care may prevent bone anchored hearing aid associated skin breakdown better than standard care of bacitracin ointment alone in adult patients.
- Trial name
- NCT03929224
- Testing
- Medicinal honey, Bacitracin
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS2 (NCT00107978)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 1,035 people
- Sponsor
- Cumberland Pharmaceuticals
Abscess
Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
The purpose of this study is to determine if soft tissue infections in pediatric patients can be more accurately diagnosed (i.e.
- Trial name
- NCT00595881
- Testing
- Bedside emergency ultrasound
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Ulcer, Venous Ulcer
The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study
Ulcers of the lower extremities, caused by chronic venous insufficiency and cellulitis are common in patients older than 65 years and cause a significant morbidity.
- Conditions
- Ulcer, Venous Ulcer, Skin Ulcer, Leg Ulcer
- Trial name
- NCT01770509
- Testing
- NMBM, Compression garments
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- M.D. Lederman Consulting Ltd